Richard Bender

Sep 17, 2015

Signal Genetics has appointed Richard Bender its chief medical officer, effective Sept. 14. He will report directly to Signal President and CEO Samuel Riccitelli.

Bender has more than 30 years of experience in clinical oncology/hematology and medical diagnostics. Most recently, he consulted for various companies and was a long-term medical affairs consultant for Quest Diagnostics. Previous to that, he was vice president and CMO at Agendia, and before that, he was the medical director of hematology/oncology at Quest in San Juan Capistrano, California. He also held management positions at Johnson & Johnson Pharmaceutical and at Permanente Medical Group.

Richard Bender

Grail Q1 Revenues up 19 Percent Driven by Clinical Test Growth

Seer Q1 Revenues Rise 35 Percent

Biodesix Q1 Revenues up 21 Percent as Firm Slashes Full-Year Guidance on Sales Restructuring

MantaBio Nabs $2.5M in Seed Funding to Develop Microbial Detection Platform for Biopharma

Socioeconomic Factors, Not Genetic Ancestry, Linked to All-Cause Mortality in Black Americans